Each year, startup.ch launches the TOP 100 STARTUP AWARD in cooperation with the Handelszeitung and PME Magazine. From over 100.000 young companies, the 100 most innovative and promising Swiss startups are picked by top startup experts. On Wednesday 14th September 2016, Amal Therapeutics reached the top10, and was elected at the rank number 8 by […]
Amongst several applications within the four partner sites, 14 candidates have been shortlisted for the 2016 Global Healthcare Innovation Academy in Calgary. Amal Therapeutics represented by Jean-François Mayol, was selected in the top 6 innovations by the Grand Jury comprised of international and local experts in science, innovation, healthcare, business, IP and marketing. Amal Therapeutics […]
Geneva, Switzerland, July 5, 2016 – Amal Therapeutics announced today that part of its recent research findings about the enhancement of anti-tumor immune responses through optimized combination of adjuvant and cellpenetrating peptide based-vaccines, is available on-line on the Molecular Therapy website on Tuesday July 5, 2016. View PDF
Geneva, Switzerland, April 8, 2016 – Amal Therapeutics, a Swiss biotech start-up company developing and progressing therapeutic vaccines in oncology, today announced the appointment of Jean-Yves Bonnefoy as new Scientific Advisory Board (SAB) member. Dr. Bonnefoy will bring over 20 years experience in Biotechnology company leadership and therapeutic cancer vaccine development. View PDF
Geneva, Switzerland, and Ingelheim, Germany, March 30, 2016 – Amal Therapeutics (Amal) completes CHF 3 million (EUR 2.75 million) Series A financing round with Boehringer Ingelheim Venture Fund (BIVF) as cornerstone investors. VI Partners and High-Tech Gründerfonds also participated in the round which will help progress Amal’s cancer vaccines. View PDF
Geneva, Switzerland, March 8, 2016 – Amal Therapeutics, a Swiss biotech start-up company developing and progressing therapeutic vaccines in oncology, today announced that it received a grant from the Swiss Commission for Technology & Innovation (CTI) to validate immunotherapies combination treatments. View PDF
Amal Therapeutics SA
c/o Fondation pour Recherches Médicales
64 av. de la Roseraie
1205 Geneva
Switzerland
Website by Instinctif Partners